|Day Low/High||9.99 / 10.01|
|52 Wk Low/High||6.02 / 10.36|
Product to Address Rising Incidence of Postpartum Hemorrhage in the US
1st product launch from the GAVIS pipeline with 180 days exclusivity
-- Company Now Eligible for Depository Services Through DTC --
Pre-clinical studies of INM-750 to commence February, 2015
Leading global investment firm KKR announced that it has signed a term sheet to provide INR10 billion (US$164.
New Entity YL Biologics to focus on clinical development and commercialization of Biosimilars for Japan